Published in Oncogene on June 23, 2005
Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) (2010) 2.48
Hepatitis B virus X gene and hepatocarcinogenesis. J Gastroenterol (2011) 1.49
Viruses associated with human cancer. Biochim Biophys Acta (2007) 1.47
Recurrent targeted genes of hepatitis B virus in the liver cancer genomes identified by a next-generation sequencing-based approach. PLoS Genet (2012) 1.38
Molecular targeted therapy for hepatocellular carcinoma: current and future. World J Gastroenterol (2013) 1.02
p100 increases AT1R expression through interaction with AT1R 3'-UTR. Nucleic Acids Res (2008) 1.02
Cooperation of tumor-derived HBx mutants and p53-249(ser) mutant in regulating cell proliferation, anchorage-independent growth and aneuploidy in a telomerase-immortalized normal human hepatocyte-derived cell line. Int J Cancer (2010) 1.00
Role of hepatitis B virus DNA integration in human hepatocarcinogenesis. World J Gastroenterol (2014) 0.98
Re-evaluation of the carcinogenic significance of hepatitis B virus integration in hepatocarcinogenesis. PLoS One (2012) 0.96
The effect of miR-338-3p on HBx deletion-mutant (HBx-d382) mediated liver-cell proliferation through CyclinD1 regulation. PLoS One (2012) 0.94
Posttranscriptional regulation of angiotensin II type 1 receptor expression by glyceraldehyde 3-phosphate dehydrogenase. Nucleic Acids Res (2009) 0.87
Dr.VIS v2.0: an updated database of human disease-related viral integration sites in the era of high-throughput deep sequencing. Nucleic Acids Res (2014) 0.81
From chronic liver disorders to hepatocellular carcinoma: Molecular and genetic pathways. World J Gastrointest Oncol (2010) 0.77
How did hepatitis B virus effect the host genome in the last decade? World J Hepatol (2014) 0.75
Association of TIP30 expression and prognosis of hepatocellular carcinoma in patients with HBV infection. Cancer Med (2016) 0.75
Multi-OMICs and Genome Editing Perspectives on Liver Cancer Signaling Networks. Biomed Res Int (2016) 0.75
Implication of the Hedgehog pathway in hepatocellular carcinoma. World J Gastroenterol (2017) 0.75
Intermediate-stage hepatocellular carcinoma patients with a high HBV-DNA load may benefit from postoperative anti-hepatitis B virus therapy. Medicine (Baltimore) (2017) 0.75
Update of research and management of hepatitis B. J Gastroenterol (2006) 0.75
The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol (2007) 4.01
Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol (2011) 2.18
Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol (2010) 2.06
Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer (2004) 2.03
A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan. J Gastroenterol (2004) 1.83
Involvement of IL-17A in the pathogenesis of DSS-induced colitis in mice. Biochem Biophys Res Commun (2008) 1.56
Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One (2012) 1.56
Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol (2011) 1.56
Coordinated ciliary beating requires Odf2-mediated polarization of basal bodies via basal feet. Cell (2012) 1.56
Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol Res (2005) 1.51
Pretreatment prediction of interferon-alfa efficacy in chronic hepatitis C patients. Clin Gastroenterol Hepatol (2005) 1.47
Correlation between cyclooxygenase-2, proliferative activity, and mucin phenotype in human advanced gastric cancer. J Gastroenterol (2004) 1.46
Efficacy and safety of sorafenib in very elderly patients aged 80 years and older with advanced hepatocellular carcinoma. Hepatol Res (2014) 1.46
Involvement of Kupffer cells in the interaction between neutrophils and sinusoidal endothelial cells in rats. Shock (2002) 1.46
Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean. PLoS One (2012) 1.44
Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology (2006) 1.43
Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology (2007) 1.39
Hepatocellular carcinoma in sustained responders of interferon-treated chronic hepatitis C. J Gastroenterol Hepatol (2003) 1.39
Peripheral neuropathy in Japanese patients with hepatitis C virus infection. Intern Med (2003) 1.38
A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol (2010) 1.32
Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. Hum Mol Genet (2011) 1.31
Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Liver Int (2006) 1.28
Lansoprazole, a proton pump inhibitor, reduces the severity of indomethacin-induced rat enteritis. Int J Mol Med (2006) 1.24
Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol (2002) 1.22
Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol (2014) 1.19
PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats. Biochem Biophys Res Commun (2004) 1.17
Lansoprazole ameliorates intestinal mucosal damage induced by ischemia-reperfusion in rats. World J Gastroenterol (2004) 1.17
Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. J Hepatol (2003) 1.17
Cytokine-induced neutrophil accumulation in the pathogenesis of acute reflux esophagitis in rats. Int J Mol Med (2005) 1.13
Reduced intestinal inflammation induced by dextran sodium sulfate in interleukin-6-deficient mice. Int J Mol Med (2004) 1.13
Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol Res (2010) 1.13
Hepatitis B virus DNA in liver, serum, and peripheral blood mononuclear cells after the clearance of serum hepatitis B virus surface antigen. J Med Virol (2004) 1.11
ERK5 is a target for gene amplification at 17p11 and promotes cell growth in hepatocellular carcinoma by regulating mitotic entry. Genes Chromosomes Cancer (2009) 1.11
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan. J Gastroenterol Hepatol (2011) 1.08
Screening of DNA copy-number aberrations in gastric cancer cell lines by array-based comparative genomic hybridization. Cancer Sci (2005) 1.08
Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease. Hepatol Res (2008) 1.08
SOX2 identified as a target gene for the amplification at 3q26 that is frequently detected in esophageal squamous cell carcinoma. Cancer Genet Cytogenet (2010) 1.07
Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol (2012) 1.04
Association of gankyrin protein expression with early clinical stages and insulin-like growth factor-binding protein 5 expression in human hepatocellular carcinoma. Hepatology (2008) 1.04
Involvement of a periodontal pathogen, Porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease. BMC Gastroenterol (2012) 1.03
High expression of p300 in HCC predicts shortened overall survival in association with enhanced epithelial mesenchymal transition of HCC cells. Cancer Lett (2011) 1.01
Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study. Hepatol Res (2014) 1.00
Ciliated hepatic foregut cyst. A report of one case and a review of the literature. Hepatol Res (2003) 0.99
Chemokine CCL20 enhances the growth of HuH7 cells via phosphorylation of p44/42 MAPK in vitro. Biochem Biophys Res Commun (2004) 0.99
Blockade of interleukin-6 signaling enhances hepatic steatosis but improves liver injury in methionine choline-deficient diet-fed mice. Lab Invest (2010) 0.98
Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A. J Clin Microbiol (2009) 0.98
Severe cytomegalovirus enterocolitis after standard chemotherapy for non-Hodgkin's lymphoma. Scand J Gastroenterol (2005) 0.97
Clinicopathological characteristics of esophageal squamous papillomas in Japanese patients--with comparison of findings from Western countries. Acta Histochem Cytochem (2006) 0.97
Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. J Gastroenterol (2011) 0.97
Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J Gastroenterol (2009) 0.97
Clinical and pathological progression of non-alcoholic steatohepatitis to hepatocellular carcinoma. Hepatol Res (2012) 0.96
Oxidative stress may enhance the malignant potential of human hepatocellular carcinoma by telomerase activation. Liver Int (2008) 0.95
Relapse of hepatitis C in a pegylated-interferon-alpha-2b plus ribavirin-treated sustained virological responder. Hepatol Res (2010) 0.95
Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. Metabolism (2010) 0.95
A novel potent inhibitor of inducible nitric oxide inhibitor, ONO-1714, reduces intestinal ischemia-reperfusion injury in rats. Nitric Oxide (2004) 0.94
Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b. J Med Virol (2011) 0.94
No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations. BMC Med Genet (2012) 0.94
Effect of a novel water-soluble vitamin E derivative as a cure for TNBS-induced colitis in rats. Int J Mol Med (2006) 0.94
Human herpesvirus 8-negative malignant effusion lymphoma: a distinct clinical entity and successful treatment with rituximab. Leuk Lymphoma (2005) 0.94
Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study. J Gastroenterol (2014) 0.93
Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011-2012. J Gastroenterol (2014) 0.93
Clear cell adenocarcinoma of the colon: a case report and review of literature. World J Gastroenterol (2008) 0.93
Effect of iron reduction by phlebotomy in Japanese patients with nonalcoholic steatohepatitis: A pilot study. Hepatol Res (2006) 0.92
Role of hepatic iron in non-alcoholic steatohepatitis. Hepatol Res (2009) 0.92
Natural course of asymptomatic hepatitis C virus-infected patients and hepatocellular carcinoma after interferon therapy. Clin Gastroenterol Hepatol (2005) 0.92
Possible involvement of RUNX3 silencing in the peritoneal metastases of gastric cancers. Clin Cancer Res (2005) 0.92
Endoscopic resection for the diagnosis of visceral Kaposi's sarcoma. J Gastroenterol (2005) 0.92
Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol (2013) 0.92
Cytokeratin 7/20 and mucin core protein expression in ulcerative colitis-associated colorectal neoplasms. Virchows Arch (2006) 0.92
Activation of B-Myb by E2F1 in hepatocellular carcinoma. Hepatol Res (2008) 0.91